Author

Stephan Miehlke 1

1 Center for Digestive Diseases, Internal Medicine Center Eppendorf,Hamburg,Germany

A 12-WEEK TREATMENT WITH BUDESONIDE ORODISPERSIBLE TABLETS IN THE EOS-1 TRIAL FOR INCOMPLETE RESPONDERS SIGNIFICANTLY IMPROVES BOTH INFLAMMATORY AND FIBROSTENOTIC ENDOSCOPIC FEATURES IN ADULT PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS

Stephan Miehlke, Alfredo J. Lucendo, Christoph Schlag, Ulrike von Arnim, Javier Molina Infante, Christoph Schmöcker, Albert Jan Bredenoord, Constanza Ciriza De Los Ríos, Stefan Brückner, Ahmed Madisch, Stefan Schubert, Jamal Hayat, Stephen E. Attwood, Jan Tack, Ralph Mueller, Roland Greinwald, Alex Straumann, Alain M. Scho

A novel budesonide orodispersible tablet formulation is highly effective to maintain endoscopic inflammatory remission and even complete endoscopic remission in adult patients with eosinophilic esophagitis: Results from the 48-weeks, double-blind, placebo-controlled pivotal EOS-2 trial

Luc Biedermann, Alfredo J. Lucendo, Stephan Miehlke, Christoph Schlag, Cecilio Santander Vaquero, Constanza Ciriza De Los Ríos, Dirk Hartmann, Ahmed Madisch, Petr Hruz, Jamal Hayat, Ulrike von Arnim, Arjan Bredenoord, Ralph Müller, Roland Greinwald, Alain Schoepfer, Stephen E. Attwood, Alex Straumann

A NOVEL BUDESONIDE ORODISPERSIBLE TABLET WITH A SPECIAL ESOPHAGEAL-TARGETING CAN INDUCE COMPLETE CLINICAL, ENDOSCOPIC AND HISTOLOGIC REMISSION IN ACTIVE EOSINOPHILIC ESOPHAGITIS: RESULTS FROM A POST-HOC ANALYSIS OF THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EOS-1 TRIAL

Stephan Miehlke

A novel budesonide orodispersible tablet with a special esophageal-targeting can induce complete clinical, endoscopic and histologic remission in active Eosinophilic Esophagitis: Results from a post-hoc analysis of the randomized, double-blind, placebo-controlled EOS-1 trial

Stephan Miehlke, Christoph Schlag, Alex Straumann, Michael Vieth, Ralph Mueller, Roland Greinwald, Alfredo J. Lucendo

A novel oral budesonide formulation is highly effective for induction of remission in patients with active eosinophilic esophagitis: Results from the 6-weeks open-label treatment phase of EOS-2 trial

Alfredo J. Lucendo, Christoph Schlag, Stephan Miehlke, Luc Biedermann, Cecilio Santander Vaquero, Dirk Hartmann, Jamal Hayat, Petr Hruz, Constanza Ciriza De Los Ríos, Arjan Bredenoord, Michael Vieth, Ralph Müller, Roland Greinwald, Alex Straumann

A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, EUROPEAN MULTICENTRE TRIAL OF TWO NEW BUDESONIDE FORMULATIONS FOR TREATMENT OF ACTIVE EOSINOPHILIC ESOPHAGITIS

Petr Hruz, Stephan Miehlke, Ulrike von Arnim, Ahmed Madisch, Michael Vieth, Christiane Fibbe, Henning Wittenburg, Hans-Dieter Allescher, Max Reinshagen, Stefan Schubert, Jan Tack, Michaela Müller, Alexander J. Eckardt, Patrick Krummenerl, Joris Arts, Karin Dilger, Roland Greinwald, Alex Straumann

BUDESONIDE IS SUPERIOR TO MESALAZINE AND PLACEBO FOR INDUCTION OF REMISSION IN LYMPHOCYTIC COLITIS

Stephan Miehlke, Daniela Aust, Emese Mihaly, Peter Armerding, Guenther Boehm, Ole Kristian Bonderup, Fernando Fernández-Bañares, Juozas Kupcinskas, Lars Kristian Munck, Kai-Uwe Rehbehn, Tanju Nacak, Roland Greinwald, Andreas Münch

BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE FIRST 48-WEEKS OPEN-LABEL EXTENSION PHASE OF THE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL

Ralph Mueller, Christoph Schlag, Christoph Schmöcker, Roland Greinwald, Luc Biedermann, Michael Vieth, Alfredo J. Lucendo, Cecilio Santander, Alex Straumann, Petr Hruz, Ahmed Madisch, Stephan Miehlke, Stephen E. Attwood, Arjan Bredenoord, Stefan Schubert, Constanza Ciriza De Los Ríos, Alain M. Schoepfer, Jamal Hayat, Ulri

BUDESONIDE ORODISPERSIBLE TABLETS ARE HIGHLY EFFECTIVE FOR RE-INDUCTION OF CLINICAL REMISSION IN RELAPSING ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE EOS-2 TRIAL

Christoph Schlag, Alex Straumann, Alfredo J. Lucendo, Stephan Miehlke, Luc Biedermann, Cecilio Santander Vaquero, Constanza Ciriza De Los Ríos, Christoph Schmöcker, Ahmed Madisch, Petr Hruz, Jamal Hayat, Ulrike von Arnim, Albert Jan Bredenoord, Ralph Mueller, Roland Greinwald, Alain M. Schoepfer, Stephen E. Attwood, Stefan

Budesonide orodispersible tablets are superior to maintain and even further improve quality of life in adult patients with eosinophilic esophagitis: Results from the 48-weeks, double-blind, placebo-controlled pivotal EOS-2 trial

Christoph Schlag, Luc Biedermann, Alfredo J. Lucendo, Stephan Miehlke, Cecilio Santander Vaquero, Constanza Ciriza De Los Ríos, Dirk Hartmann, Ahmed Madisch, Petr Hruz, Jamal Hayat, Ulrike von Arnim, Arjan Bredenoord, Ralph Müller, Roland Greinwald, Alain Schoepfer, Stephen E. Attwood, Alex Straumann

Item 1 - 10 / 38
1
2 3 4